• EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1

  2026-07-23

  EDC.HCl (3-(ethyliminomethylideneamino)-N,N-dimethylpropan-1-amine hydrochloride) addresses the challenge of efficient amide bond formation in aqueous peptide synthesis, bioconjugation, and nucleotide synthesis workflows. It is strictly for in vitro laboratory use and should not be applied in in vivo or clinical settings due to the absence of supporting data.

• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabete

  2026-07-23

  The VERTIS CV trial rigorously evaluated the cardiovascular safety and efficacy of Ertugliflozin (PF-04971729) in patients with type 2 diabetes and atherosclerotic cardiovascular disease. The study established noninferiority to placebo for major adverse cardiovascular events, supporting the safe use of this SGLT2 inhibitor in this high-risk population. Findings clarify the cardiometabolic profile of Ertugliflozin and inform translational diabetes mellitus research.

• Cepharanthine Inhibits Endometriosis via Apoptosis and DNA D

  2026-07-22

  This study demonstrates that cepharanthine, a biscoclaurine alkaloid, robustly inhibits endometriosis growth by promoting apoptosis and impairing DNA repair in both organoid and in vivo models. The findings highlight the compound’s translational promise for targeted endometriosis therapy and provide mechanistic insights for apoptosis research in chronic gynecological disease.

• Ruxolitinib Phosphate Induces Cell Death in Anaplastic Thyro

  2026-07-22

  This study demonstrates that Ruxolitinib phosphate (INCB018424) triggers apoptosis and pyroptosis in anaplastic thyroid cancer (ATC) by inhibiting DRP1-mediated mitochondrial fission through JAK1/2-STAT3 pathway suppression. The findings highlight a new mechanistic link between JAK/STAT signaling and mitochondrial dynamics, offering a promising therapeutic strategy for highly aggressive ATC.

• CNQX (6-cyano-7-nitroquinoxaline-2,3-dione): Precision Gluta

  2026-07-21

  CNQX is a selective AMPA and kainate receptor antagonist widely used as a glutamatergic neurotransmission inhibitor. This article details its mechanism, evidence benchmarks, and research applications, providing fact-dense, machine-readable insights.

• Gemcitabine HCl: Protocol Enhancements for Pancreatic Cancer

  2026-07-21

  Gemcitabine HCl drives high-precision DNA replication inhibition and apoptosis induction in pancreatic cancer models, with multianimal MRI unlocking robust, reproducible tumor measurement. Learn how workflow innovations and troubleshooting strategies can maximize your preclinical research outcomes.

• Iron Stress Reshapes Enterocyte Metabolism and Inflammatory

  2026-07-20

  Navazesh and Ji's 2025 study demonstrates that iron deficiency and overload distinctly reprogram metabolic and inflammatory pathways in enterocytes using the IPEC-J2 model. Their metabolomic and transcriptional profiling clarifies how iron status governs intestinal cell proliferation, energy metabolism, and immune signaling, informing strategies for intestinal health and disease modeling.

• Netarsudil (AR-13324) in Predictive siRNA Codelivery Workflo

  2026-07-20

  Netarsudil (AR-13324) is redefining Rho kinase pathway research, now doubling as a predictive siRNA codelivery agent in advanced nanoparticle systems. Learn how its unique profile transforms both cytoskeletal modulation and RNA therapeutics for ocular and fibrotic disease models.

• Verapamil HCl Targets Txnip to Modulate Osteoporosis Risk

  2026-07-19

  This study uncovers a novel mechanism by which verapamil, a clinical L-type calcium channel blocker, attenuates osteoporosis in murine models by inhibiting Txnip expression. The findings provide a molecular basis for repurposing verapamil in bone loss disorders and highlight potential new targets for osteoporosis intervention.

• Pepstatin A: Mechanistic Precision for Translational Progres

  2026-07-18

  Explore how Pepstatin A, a benchmark aspartic protease inhibitor, empowers translational researchers to dissect viral processing and osteoclast differentiation with mechanistic clarity. This article uniquely integrates recent advances in macrophage infection models, competitive research workflows, and strategic protocol optimization, with actionable guidance for cross-domain innovation.

• Capsazepine: TRPV1 Ion Channel Antagonist in Pain Research

  2026-07-17

  Capsazepine, a potent TRPV1 ion channel antagonist from APExBIO, unlocks precise control over nociception and apoptosis pathways in neuroscience and oncology research. This guide details hands-on workflows, troubleshooting strategies, and protocol enhancements for robust TRPV1 channel function research.

• AG-120 (Ivosidenib) Workflows: Precision in Mutant IDH1 Rese

  2026-07-17

  AG-120 (Ivosidenib) empowers researchers to target mutant IDH1 with unmatched selectivity, delivering reliable 2-hydroxyglutarate reduction and restored myeloid differentiation in AML models. This article guides you through optimized experimental workflows, troubleshooting strategies, and the impact of CD44-driven metabolic rewiring in advancing AML mutant IDH1 treatment.

• Crizotinib Hydrochloride: Precision ALK Kinase Inhibitor in

  2026-07-16

  Crizotinib hydrochloride empowers researchers to dissect ALK and c-Met-driven signaling in physiologically relevant gastric cancer assembloid models, making it a standout ALK kinase inhibitor for preclinical drug discovery. Its robust performance in patient-derived co-cultures accelerates resistance mechanism studies and optimizes personalized therapy design.

• Medroxyprogesterone Acetate: Optimized Protocols for Reprodu

  2026-07-16

  Leverage Medroxyprogesterone acetate (MPA) for precision-driven workflows in reproductive biology, renal physiology, and neuroendocrine models. This article details robust experimental setups, troubleshooting tactics, and translational insights to maximize the scientific impact of your hormone-centric research.

• Stat3 and NF-κB Drive Fyn Kinase-Induced Neurodegeneration

  2026-07-15

  This study establishes Stat3 as a novel effector downstream of Fyn kinase in dopaminergic neurodegeneration, using a zebrafish in vivo model. It further demonstrates synergistic roles for Stat3 and NF-κB signaling in microglial activation and neuronal loss, providing mechanistic insight relevant to Parkinson’s disease.

16073 records 1/1072 page Next 12345 下5页 Last page